ALXO News and Press, ALX Oncology Holdings Inc. From 06/29/22

SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administ...

– Expansion of solid tumor clinical program – ASPEN-02 dose optimization data to inform dosing for ASPEN-05 SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clin...

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, Pre...

ALX Oncology press release (NASDAQ:ALXO): Q1 GAAP EPS of -$0.60 beats by $0.11. Cash, cash equivalents and investments as of March 31, 2022 were $341.7 million. ALX Oncology believes its cash, cash equivalents and investments are sufficient to fund planned operations through mid-2024. For f...

SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarte...

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas...

ALX Oncology Holdings Inc. (NASDAQ:ALXO) traded today at a new 52-week high of $117.45. Approximately 4.1 million shares have changed hands today, as compared to an average 30-day volume of 362,000 shares. ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on h...

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) traded at a new 52-week high today of $117.45. Approximately 4.1 million shares have changed hands today, as compared to an average 30-day volume of 397,000 shares. In the past 52 weeks, shares of ALX Oncology Holdings Inc. have traded b...

ALX Oncology Holdings (NASDAQ:ALXO) has filed for a $450M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company will indicate how it will use the proceeds in a prospectus supplement. The offering can include common ...

ALX Oncology (NASDAQ:ALXO) said the first patient was dosed in a  phase 2/3 ASPEN-06 trial evaluating its drug evorpacept and Eli Lilly's (NYSE:LLY) Cyramza (ramucirumab), added to trastuzumab and paclitaxel to treat patients with HER2-positive gastric cancer or gastroesophagea...